App-Quantinova.ai

Alkaline phosphatase as a predictor of giant cell arteritis – a retrospective analysis of clinical features and temporal artery biopsy findings

S. Varrier - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Giant cell arteritis

Alkaline phosphatase

An audit for screening of osteoporosis and its management in patients with systemic lupus erythematosus

S.A. Syed - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Association between fracture sites in patients with a history of parental fracture

M. Dey - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Giant cell arteritis

Medroxyprogesterone

Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers

D. Jayne - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Wegener's granulomatosis

Cyclophosphamide

Certolizumab pegol provides sustained remission and minimal disease activity in patients with psoriatic arthritis over 4 years’ treatment

D. van der Heijde - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

Certolizumab pegol

Changes in lymphocytes and lymphocyte subsets in tofacitinib-treated patients with psoriatic arthritis

G. Burmester - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

Tasocitinib

Characterising a mouse model of temporomandibular joint (TMJ arthritis to study orofacial pain and inflammation

X. Kodji - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

Isoflurane

Clinically meaningful improvement in skin and nail psoriasis in bio-naÏve active psoriatic arthritis patients treated with intravenous golimumab: results through week 24 of the go-vibrant study

P.J. Mease - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

golimumab

Cxcl10/cxcl11 serum measurement as potential predictor of systemic sclerosis

C. Antinozzi - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

IFN-lambda

Development of metabolic syndrome in patients with sle: results from an inception cohort

A. Mohammed - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Metabolic syndrome

Interleukin

Differential complement activation in rheumatoid arthritis patients

T.C.R. Mcdonnell - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Protein C

Differential methylation as a predictor of methotrexate response in patients with rheumatoid arthritis

N. Nair - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Methotrexate

Dynamic contrast enhanced mr imaging in early stage knee osteoarthritis: a test-retest repeatability study in healthy and moderately diseased subjects

F. Sanaei Nezhad - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Knee osteoarthritis

Gadoterate meglumine

Dynamics of circulating tnf during adalimumab treatment of rheumatoid arthritis using a novel drug-tolerant tnf assay

L. C. Berkhout - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Adalimumab

Effect of tofacitinib on reducing pain in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

A. Ogdie - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

Tasocitinib

Efficacy of sarilumab in patients with rheumatoid arthritis with and without previous response to tocilizumab

P. Verschueren - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Tocilizumab

Examining the role of trpc5 in osteoarthritis pain

J. Sousa-Valente - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

thioredoxin

Expression of ifn type i responsive genes in a cardiovascular disease continuum of rheumatoid arthritis

A.N. Burska - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Interferon

“as a practitioner i feel enriched”: rheumatology tutors’ experiences of delivering a manualised group cognitive-behavioural fatigue programme to patients with rheumatoid arthritis (RA

E. Dures - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

‘real life’ biological drug tapering results in few flares of disease and significant cost savings

S. Batool - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Filters

45280 Abstracts